logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Tag: Abeona Therapeutics (ABEO)

Halozyme: Helping Immunotherapy Products. Abeona: An Attractive Newcomer to the Stock Market

Halozyme Therapeutics ( HALO )  announced that it will present nonclinical data at the 32 nd  Annual Meeting of the Society for Immunotherapy of Cancer (SITC) which demonstrate the potential for PEGPH20, Halozyme's pegylated recombinant human hyaluronidase, to increase the...

Read More

November 10, 2017

0

Halozyme: Helping Immunotherapy Products. Abeona: An Attractive Newcomer to the Stock Market

Halozyme Therapeutics ( HALO )  announced that it will present nonclinical data at the 32 nd  Annual Meeting of the Society for Immunotherapy of Cancer (SITC) which demonstrate the potential for PEGPH20, Halozyme's pegylated recombinant human hyaluronidase, to increase the...

Read More

November 10, 2017

0

RegenxBio: Another licensing agreement providing additional validation of its NAV platform

RegenxBio (RGNX)  has granted  Abeona Therapeutics (ABEO) an exclusive worldwide license to its NAV AAV9 viral vector (subject to certain non-exclusive rights previously granted for MPS IIIA) for the treatment of four diseases: Sanfilippo syndrome type A (MPS IIIA) and type B...

Read More

November 5, 2018

0

RegenxBio: Another licensing agreement providing additional validation of its NAV platform

RegenxBio (RGNX)  has granted  Abeona Therapeutics (ABEO) an exclusive worldwide license to its NAV AAV9 viral vector (subject to certain non-exclusive rights previously granted for MPS IIIA) for the treatment of four diseases: Sanfilippo syndrome type A (MPS IIIA) and type B...

Read More

November 5, 2018

0

Halozyme: Helping Immunotherapy Products. Abeona: An Attractive Newcomer to the Stock Market

Halozyme Therapeutics ( HALO )  announced that it will present nonclinical data at the 32 nd  Annual Meeting of the Society for Immunotherapy of Cancer (SITC) which demonstrate the potential for PEGPH20, Halozyme's pegylated recombinant human hyaluronidase, to increase the...

Read More

November 10, 2017

0

Small Biotech Firms That Can Become Top-Tier Giants

Small Biotech Firms That Can Become Top-Tier Biotech Giants We Start With... Abeona Therapeutics Abeona Therapeutics ( ABEO )   is a clinical-stage biopharmaceutical gene and cell therapy company. In September 2016 Abeona acquired an exclusive  worldwide license of a...

Read More

July 2, 2019

0

Small Biotech Firms That Can Become Top-Tier Giants

Small Biotech Firms That Can Become Top-Tier Biotech Giants We Start With... Abeona Therapeutics Abeona Therapeutics ( ABEO )   is a clinical-stage biopharmaceutical gene and cell therapy company. In September 2016 Abeona acquired an exclusive  worldwide license of a...

Read More

July 2, 2019

0

RegenxBio: Another licensing agreement providing additional validation of its NAV platform

RegenxBio (RGNX)  has granted  Abeona Therapeutics (ABEO) an exclusive worldwide license to its NAV AAV9 viral vector (subject to certain non-exclusive rights previously granted for MPS IIIA) for the treatment of four diseases: Sanfilippo syndrome type A (MPS IIIA) and type B...

Read More

November 5, 2018

0

Small Biotech Firms That Can Become Top-Tier Giants

Small Biotech Firms That Can Become Top-Tier Biotech Giants We Start With... Abeona Therapeutics Abeona Therapeutics ( ABEO )   is a clinical-stage biopharmaceutical gene and cell therapy company. In September 2016 Abeona acquired an exclusive  worldwide license of a...

Read More

July 2, 2019

0

  • 1

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy